肝细胞癌手术及局部治疗中系统治疗临床试验的专家共识
HCC-Live联盟召集多学科专家,针对围手术期系统治疗及局部联合系统治疗试验的入组标准、风险分层、治疗臂和终点形成共识,以>70%赞成定义为共识。共达成9条新辅助/围手术期和9条联合治疗共识,强调精选人群、平衡疗效安全及使用临床相关终点。
要点
- 新辅助/围手术期试验应纳入复发风险最高患者,主要终点推荐2年无事件生存率(限制性平均生存时间)。
- 联合治疗试验应纳入同质人群,大肿瘤负荷/局部晚期患者推荐系统治疗为对照臂。
- 联合试验主要终点推荐无进展生存期和总生存期,采用α循环策略,次要终点不可或缺。
核心结论
- 优化HCC试验设计对严谨评估系统治疗在手术切除或联合局部治疗中的作用至关重要。
研究设计与样本
- HCC-Live联盟召集多学科癌症专家组成专家组,共识定义为获得>70%专家赞成。
主要发现
- 专家组就新辅助或围手术期系统治疗达成9条共识声明,就局部联合系统治疗达成9条共识声明。
关键数值与推荐
- 新辅助/围手术期试验主要终点推荐2年无事件生存率,采用限制性平均生存时间。
- 联合治疗试验主要终点推荐无进展生存期和总生存期,采用α循环策略。
- 大肿瘤负荷和局部晚期患者推荐系统治疗作为对照臂。
临床怎么用
- 试验应招募精心选择的人群,采用兼顾疗效与安全的治疗策略和 duration。
- 联合治疗试验应纳入同质患者人群,对照臂需与临床实践一致。
- 次要终点对指导临床适用性至关重要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advances in systemic therapy for advanced hepatocellular carcinoma (HCC) have fuelled a growing interest in evaluating these therapies in earlier stages of disease. However, trial design remains challenging due to the marked clinical and biological heterogeneity of early-stage and intermediate-stage HCC. OBJECTIVE: A multidisciplinary group of cancer experts was convened by the HCC-Live Consortium to discuss inclusion criteria, risk stratification, treatment arms and appropriate endpoints of trials evaluating perioperative and combination therapies in patients with HCC. DESIGN: Consensus statements were defined as those obtaining >70% approval by panellists. RESULTS: The panel achieved consensus regarding nine consensus statements for neoadjuvant or perioperative systemic therapy and nine statements for combination locoregional plus systemic therapy. Statements emphasised recruiting carefully selected patient populations, employing treatment strategies and duration that balance efficacy with safety and using clinically relevant endpoints. Trials evaluating neoadjuvant/perioperative approaches should include patients at the highest risk of recurrence, with a recommended primary outcome of 2-year event-free survival using restricted mean survival time. Trials evaluating combination therapies should include a homogeneous patient population and use an appropriate comparator arm that aligns with clinical practice. Specifically, systemic therapy was the recommended comparator arm for patients with larger tumour burden and locally advanced disease. The recommended primary outcome for combination trials was progression-free survival and overall survival, with an alpha-recycling strategy. Secondary endpoints are essential to inform clinical applicability. CONCLUSION: Optimal design of HCC trials is important to rigorously evaluate the role of systemic therapy in patients undergoing surgical resection or in combination with locoregional therapy.
引用
- Yarchoan M, Llovet JM, Kelley RK, et al. Expert consensus on clinical trials for use of systemic therapy in patients with hepatocellular carcinoma undergoing surgical and locoregional therapies. Gut. 2026. PMID: 42785981. doi:10.1136/gutjnl-2026-339505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。